Exenatide Research
Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy
Annals of Neurology·November 1, 2025
Nirosen Vijiaratnam, Christine Girges, Martin Wiegand, et al., Tom Foltynie
Summary
Exenatide group showed improved UMSARS scores (6.1 vs 13.3 points worsening, difference -7.4, p=0.0003). Potential placebo effects given open-label design.
Study Details
Study Design
Single-center, randomized, open-label trial
Indication
Multiple System Atrophy (MSA)
Intervention
Subcutaneous exenatide 2 mg weekly for 48 weeks vs standard care
Species
Human
Sample Size
50 subjects